title: Clinical Psychopharmacology Update: What's in a Name? Confusion Prompts Change for Vortioxetine's Brand Name.
abstract: Similar names between two unrelated drugs have led the FDA to issue warnings about and now approve a name change for vortioxetine, which was branded as Brintellix® until recently. While the trade name had been screened prior to the product's launch, the FDA received numerous reports of prescribing and dispensing errors, specifically with regard to the anti-coagulant drug Brilinta® (ticagrelor). Starting 1 June 2016, vortioxetine will be marketed under the name Trintellix™ in an effort to reduce confusion. Clinicians are advised that while the name and National Drug Code number with this product will change, it will retain the same formulation, indication, and dosage information. To the extent possible, clinicians can and should take actions to identify and reduce potential medication errors in prescriptions, especially when using electronic records and e-prescription systems.
authors.affiliation: a Harvard University , Cambridge , Massachusetts , USA.
authors.forename: Thomas J
authors.initials: TJ
authors.lastname: Tobin
authors.affiliation: b Private Practice , North Myrtle Beach, South Carolina , USA.
authors.forename: Mary L
authors.initials: ML
authors.lastname: Tobin